These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 15494019)
1. A molecular cell biology of lithium. Williams R; Ryves WJ; Dalton EC; Eickholt B; Shaltiel G; Agam G; Harwood AJ Biochem Soc Trans; 2004 Nov; 32(Pt 5):799-802. PubMed ID: 15494019 [TBL] [Abstract][Full Text] [Related]
2. A common mechanism of action for three mood-stabilizing drugs. Williams RS; Cheng L; Mudge AW; Harwood AJ Nature; 2002 May; 417(6886):292-5. PubMed ID: 12015604 [TBL] [Abstract][Full Text] [Related]
3. The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporters. Di Daniel E; Cheng L; Maycox PR; Mudge AW Mol Cell Neurosci; 2006; 32(1-2):27-36. PubMed ID: 16531065 [TBL] [Abstract][Full Text] [Related]
4. PtdIns(3,4,5)P(3) and inositol depletion as a cellular target of mood stabilizers. Teo R; King J; Dalton E; Ryves J; Williams RS; Harwood AJ Biochem Soc Trans; 2009 Oct; 37(Pt 5):1110-4. PubMed ID: 19754462 [TBL] [Abstract][Full Text] [Related]
5. The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior. Shimshoni JA; Dalton EC; Jenkins A; Eyal S; Ewan K; Williams RS; Pessah N; Yagen B; Harwood AJ; Bialer M Mol Pharmacol; 2007 Mar; 71(3):884-92. PubMed ID: 17167030 [TBL] [Abstract][Full Text] [Related]
6. Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death. Jin N; Kovács AD; Sui Z; Dewhurst S; Maggirwar SB Neuropharmacology; 2005 Mar; 48(4):576-83. PubMed ID: 15755485 [TBL] [Abstract][Full Text] [Related]
8. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. Harwood AJ Mol Psychiatry; 2005 Jan; 10(1):117-26. PubMed ID: 15558078 [TBL] [Abstract][Full Text] [Related]
9. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Hall AC; Brennan A; Goold RG; Cleverley K; Lucas FR; Gordon-Weeks PR; Salinas PC Mol Cell Neurosci; 2002 Jun; 20(2):257-70. PubMed ID: 12093158 [TBL] [Abstract][Full Text] [Related]
10. GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid. Jonathan Ryves W; Dalton EC; Harwood AJ; Williams RS Bipolar Disord; 2005 Jun; 7(3):260-5. PubMed ID: 15898963 [TBL] [Abstract][Full Text] [Related]
11. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Chuang DM Ann N Y Acad Sci; 2005 Aug; 1053():195-204. PubMed ID: 16179524 [TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons. Di Daniel E; Mudge AW; Maycox PR Bipolar Disord; 2005 Feb; 7(1):33-41. PubMed ID: 15654930 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of glycogen synthase kinase 3beta in sensory neurons in culture alters filopodia dynamics and microtubule distribution in growth cones. Owen R; Gordon-Weeks PR Mol Cell Neurosci; 2003 Aug; 23(4):626-37. PubMed ID: 12932442 [TBL] [Abstract][Full Text] [Related]
14. Investigation of the H(+)-myo-inositol transporter (HMIT) as a neuronal regulator of phosphoinositide signalling. Di Daniel E; Kew JN; Maycox PR Biochem Soc Trans; 2009 Oct; 37(Pt 5):1139-43. PubMed ID: 19754467 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effects of propylisopropylacetic acid (PIA) on neuronal growth cone morphology. Shimshoni JA; Dalton EC; Watson P; Boris Y; Bialer M; Harwood AJ Neuropharmacology; 2009 Mar; 56(4):831-7. PubMed ID: 19705552 [TBL] [Abstract][Full Text] [Related]
16. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders. Kozikowski AP; Gaisina IN; Yuan H; Petukhov PA; Blond SY; Fedolak A; Caldarone B; McGonigle P J Am Chem Soc; 2007 Jul; 129(26):8328-32. PubMed ID: 17552518 [TBL] [Abstract][Full Text] [Related]
17. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Gould TD; Quiroz JA; Singh J; Zarate CA; Manji HK Mol Psychiatry; 2004 Aug; 9(8):734-55. PubMed ID: 15136794 [TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. Gould TD; Zarate CA; Manji HK J Clin Psychiatry; 2004 Jan; 65(1):10-21. PubMed ID: 14744163 [TBL] [Abstract][Full Text] [Related]
19. How can the mood stabilizer VPA limit both mania and depression? Cheng L; Lumb M; Polgár L; Mudge AW Mol Cell Neurosci; 2005 Jun; 29(2):155-61. PubMed ID: 15911340 [TBL] [Abstract][Full Text] [Related]
20. The effects of collapsing factors on F-actin content and microtubule distribution of Helisoma growth cones. Torreano PJ; Waterman-Storer CM; Cohan CS Cell Motil Cytoskeleton; 2005 Mar; 60(3):166-79. PubMed ID: 15700278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]